{"id":"NCT02604810","sponsor":"Grifols Therapeutics LLC","briefTitle":"Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency","officialTitle":"An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01","primaryCompletion":"2017-09","completion":"2017-12","firstPosted":"2015-11-13","resultsPosted":"2019-10-04","lastUpdate":"2019-10-04"},"enrollment":53,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency"],"interventions":[{"type":"BIOLOGICAL","name":"IGIV-C 10%","otherNames":["Immune Globulin Injection 10% Caprylate/Chromatography"]},{"type":"BIOLOGICAL","name":"IGSC 20%","otherNames":["Immune Globulin Subcutaneous 20% Caprylate/Chromatography"]}],"arms":[{"label":"IGIV-C 10%","type":"ACTIVE_COMPARATOR"},{"label":"IGSC 20%","type":"EXPERIMENTAL"}],"summary":"This study was designed to determine a dose of weekly subcutaneously administered Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols) (IGSC 20%) that produces steady-state AUC of total IgG that was non-inferior to that of the regularly administered intravenous dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols) (IGIV-C 10%) in primary immunodeficiency subjects. This study was also designed to determine steady state trough total IgG levels after IGSC 20% infusion and after IGIV-C 10% infusion for comparison and to assess the safety and tolerability of IGSC 20%.","primaryOutcome":{"measure":"AUC in the IV Phase and SC Phases: Steady-state AUC of Total IgG Over a Regular Dosing Interval","timeFrame":"For intravenous infusion, predose, 0,1,3-16 hours and 1,2,3,5,7,14,21 or 28 days (2, 7, 21, or 28 days for pediatric subjects) post-dose and for subcutaneous infusion, pre-dose,1,3,4,5,7 days (3 and 7 days for pediatric subjects) post-dose","effectByArm":[{"arm":"IGIV-C 10%","deltaMin":207921.5,"sd":null},{"arm":"IGSC 20%","deltaMin":213141.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":25,"countries":["United States","Canada"]},"refs":{"pmids":["31621458"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":52},"commonTop":["Sinusitis","Infusion site nodule","Bronchitis","Upper respiratory tract infection","Cough"]}}